Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study
Authors' conclusion
All three drugs displayed good glucose-lowering efficacy and comparable safety profiles. However, dapagliflozin therapy produced favorable changes in body composition. Dapagliflozin may be a suitable adjunct therapy for patients with type 2 diabetes seeking to improve their body composition.
Study context
- Population
- Patients with T2D uncontrolled despite metformin and SU therapy
- Participants
- 26 / 26 / 26
- Comparison
- Sitagliptin vs dapagliflozin vs lobeglitazone as add-on to metformin and SU
- Sitagliptinn = 26
- Dapagliflozinn = 26
- Lobeglitazonen = 26
- Primary endpoint
- Change in HbA1c
- Follow-up
- 24 months
Methodological detailsthree-arm
- Three-arm
Primary result
As reported in the abstract
Mean change in HbA1c
Sitagliptin
−0.81
mean · ± 0.21 · %
Dapagliflozin
−1.05
mean · ± 0.70 · %
Lobeglitazone
−1.08
mean · ± 0.98 · %
Further findings
Systolic blood pressure
- Dapagliflozin significantly lowered systolic blood pressure
- 5.5 mmHg
Alanine aminotransferase
- Dapagliflozin significantly lowered alanine aminotransferase levels
Proteinuria and insulin resistance
- Dapagliflozin and lobeglitazone significantly reduced proteinuria and insulin resistance
Change in whole body fat percentage
- Dapagliflozin decreased whole body fat percentage
- 1.2%
- Sitagliptin increased whole body fat percentage
- 1.1%
- Lobeglitazone increased whole body fat percentage
- 1.8%
Whole body muscle percentage
- Increased with dapagliflozin and decreased with lobeglitazone
Safety
- Safety profiles of the three treatments were comparable
Original publication
Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study. Diabetes Res Clin Pract. Published 11 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →